Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis

Imagem de Miniatura
Arquivos
art_SANTOS_Characterization_of_primary_directacting_antiviral_DAA_drugs_resistance_2022.PDF (214.2 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
SILVA, Vanessa Cristina Martins
LEMOS, Marcilio Figueiredo
SANTANA, Rubia Anita Ferraz
DASTOLI, Gregorio Tadeu Fernando
CASTRO, Vanessa Fusco Duarte de
MOREIRA, Regina Celia
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.64, article ID e61, 9p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The Hepatitis C virus (HCV) infection is a public health problem. The high level of HCV replication and its lack of post-transcriptional correction mechanisms results in the emergence of viral variants and the difficulty in determining polymorphisms and variants that contain the substitutions associated with resistance towards new antivirals. The main focus of this study was to map the NS5A and NS5B polymorphisms and resistance mutations to new antiviral drugs in HCV strains genotype 1 from patients with chronic hepatitis C infection. Serum samples were collected from patients who underwent routine viral load tests at the Instituto Adolfo Lutz, Sao Paulo city, Brazil. A total of 698 and 853 samples were used for the characterization of NS5A and NS5B regions, respectively, which comprise the HCV genotypes la and lb. The prevalence of resistance mutations found in the NS5A region was 6.4%, with Y93H, L31M, Q30R, and Y93N as the main resistance-associated substitutions (RAS). No NS5B-associated RAS was observed for any of the analyzed drugs. These findings support that the RAS test should be offered to individuals with poor response to double combination regimens prior to treatment initiation, thereby assisting strain vigilance and selection of effective treatment or retreatment options using DAA regimens.
Palavras-chave
DAA, Hepatitis C virus, Genotype 1, RAS, NS5B, NS5A
URI
https://observatorio.fm.usp.br/handle/OPI/50561
Referências
  1. Aguiar BF, 2020, CLIN RES HEPATOL GAS, V44, P329, DOI 10.1016/j.clinre.2019.07.015
  2. Aldunate F, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/2514901
  3. Andre-Garnier E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179562
  4. Bhattacharjee Chayan, 2021, VirusDisease, V32, DOI 10.1007/s13337-021-00697-0
  5. Blach S, 2022, LANCET GASTROENTEROL, V7, P396, DOI 10.1016/S2468-1253(21)00472-6
  6. Borgia SM, 2018, J INFECT DIS, V218, P1722, DOI 10.1093/infdis/jiy401
  7. Brasil. Ministerio da Saude, 2015, DEP VIG PREV CONTR I
  8. Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
  9. Chen CY, 2021, LIVER INT, V41, P1265, DOI 10.1111/liv.14849
  10. Cheng GF, 2016, ANTIMICROB AGENTS CH, V60, P1847, DOI 10.1128/AAC.02524-15
  11. Costa VD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216327
  12. Cuypers L, 2016, REV MED VIROL, V26, P408, DOI 10.1002/rmv.1895
  13. Santos APD, 2021, INFECT DRUG RESIST, V14, P723, DOI 10.2147/IDR.S247071
  14. Di Maio VC, 2021, LIVER INT, V41, P1802, DOI 10.1111/liv.14797
  15. Di Stefano M, 2021, NEW MICROBIOL, V44, P12
  16. Eltahla AA, 2017, SCI REP-UK, V7, DOI 10.1038/srep41719
  17. Esposito I, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010003
  18. Foster GR, 2016, J HEPATOL, V64, P1224, DOI 10.1016/j.jhep.2016.01.029
  19. Gottwein JM, 2018, GASTROENTEROLOGY, V154, P1435, DOI 10.1053/j.gastro.2017.12.015
  20. Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
  21. Jimenez-Perez M, 2016, WORLD J GASTROENTERO, V22, P6573, DOI 10.3748/wjg.v22.i29.6573
  22. Kalaghatgi P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155869
  23. Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
  24. Liu ZQ, 2020, J VIRAL HEPATITIS, V27, P585, DOI 10.1111/jvh.13270
  25. Malta F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2817-7
  26. Meshram RJ, 2022, ARCH VIROL, V167, P717, DOI 10.1007/s00705-022-05375-0
  27. Noble CF, 2017, ARCH VIROL, V162, P165, DOI 10.1007/s00705-016-3094-2
  28. Peres-da-Silva A, 2015, J ANTIMICROB CHEMOTH, V70, P726, DOI 10.1093/jac/dku462
  29. Rao HY, 2020, J CLIN TRANSL HEPATO, V8, P255, DOI 10.14218/JCTH.2020.00031
  30. Sagnelli E, 2018, INFECTION, V46, P761, DOI 10.1007/s15010-018-1188-3
  31. Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
  32. SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
  33. Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
  34. Sarrazin C, 2014, Z GASTROENTEROL, V52, P1185, DOI 10.1055/s-0033-1362816
  35. Sayan M, 2020, INT J INFECT DIS, V95, P84, DOI 10.1016/j.ijid.2020.03.061
  36. Sharafi H, 2018, WORLD J HEPATOL, V10, P543, DOI 10.4254/wjh.v10.i9.543
  37. Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
  38. Sorbo MC, 2018, DRUG RESIST UPDATE, V37, P17, DOI 10.1016/j.drup.2018.01.004
  39. Suzuki F, 2012, J CLIN VIROL, V54, P352, DOI 10.1016/j.jcv.2012.04.024
  40. Wyles David L, 2017, Top Antivir Med, V25, P103

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03